Journal Article
. 2015 Feb; 23(3):499-509.
doi: 10.1007/s12282-015-0593-z.

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Eiichi Shiba 1 Hiroko Yamashita 2 Junichi Kurebayashi 3 Shinzaburo Noguchi 4 Hirotaka Iwase 5 Yasuo Ohashi 6 Kiyofumi Sasai 7 Tsukasa Fujimoto 7 
Affiliations
  • PMID: 25655898
  •     22 References
  •     8 citations

Abstract

Background: Luteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist, leuprorelin.

Methods: We conducted an open-label, randomized controlled pilot study to evaluate the safety and efficacy of leuprorelin subcutaneously administered every-3-months for 2 versus 3 or more, up to 5 years, together with daily tamoxifen for 5 years in premenopausal endocrine-responsive breast cancer patients. Primary endpoints were disease-free survival (DFS) and safety.

Results: Eligible patients (N = 222) were randomly assigned to receive leuprorelin for either 2 years (N = 112) or 3 or more years (N = 110) with tamoxifen for 5 years after surgery. Leuprorelin treatment for 3 or more years provided no significant difference in DFS rate over 2 years: 94.1 versus 91.8 % at 144 weeks (3 years) after the second year (week 96) and 90.8 versus 90.4 % at the fifth year (week 240). The overall survival rate was 100 % for both groups during the third through fifth year study period. There were no significant differences in the incidence of adverse events (AEs) between the 2 groups: most AEs were rated grade 1 or 2.

Conclusions: Adjuvant leuprorelin treatment for 3 or more years with tamoxifen showed a survival benefit and safety profile similar to that for 2 years in premenopausal endocrine-responsive breast cancer patients. No new safety signal was identified for long-term leuprorelin treatment. Longer follow-up observation is needed to determine the optimal duration of leuprorelin treatment.

Keywords: Adjuvant endocrine therapy; Disease-free survival (DFS); Leuprorelin acetate; Premenopausal endocrine-responsive breast cancer; Safety.

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
W Jonat, M Kaufmann, +14 authors, Zoladex Early Breast Cancer Research Association Study.
J Clin Oncol, 2002 Dec 19; 20(24). PMID: 12488406
[Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
T Taguchi, H Koyama, +7 authors, K Enomoto.
Gan To Kagaku Ryoho, 1995 Mar 01; 22(4). PMID: 7887641
[A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
T Taguchi, H Koyama, +7 authors, K Enomoto.
Gan To Kagaku Ryoho, 1995 Mar 01; 22(4). PMID: 7887640
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Nancy E Davidson, Anne M O'Neill, +4 authors, Martin D Abeloff.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087950
Hormonal therapies in young breast cancer patients: when, what and for how long?
Alexandre Christinat, Simona Di Lascio, Olivia Pagani.
J Thorac Dis, 2013 Jul 03; 5 Suppl 1. PMID: 23819026    Free PMC article.
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Peter Schmid, Michael Untch, +8 authors, Kurt Possinger.
J Clin Oncol, 2007 Jun 20; 25(18). PMID: 17577027
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
J G Klijn, R W Blamey, +4 authors, Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer.
J Clin Oncol, 2001 Feb 24; 19(2). PMID: 11208825
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
M Dowsett, A Mehta, J Mansi, I E Smith.
Br J Cancer, 1990 Nov 01; 62(5). PMID: 2123115    Free PMC article.
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years.
H J Stewart, R J Prescott, A P Forrest.
J Natl Cancer Inst, 2001 Mar 22; 93(6). PMID: 11259471
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Michael Gnant, Brigitte Mlineritsch, +18 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Lancet Oncol, 2008 Aug 23; 9(9). PMID: 18718815
Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.
M Baum, A Hackshaw, +6 authors, ZIPP International Collaborators Group.
Eur J Cancer, 2006 Mar 21; 42(7). PMID: 16545560
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.
F Boccardo, A Rubagotti, +10 authors, P Marroni.
Cancer Chemother Pharmacol, 1999 May 13; 43(6). PMID: 10321505
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
A Goldhirsch, J H Glick, +2 authors, H J Senn.
J Clin Oncol, 2001 Sep 18; 19(18). PMID: 11559719
Review.
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
H J Stewart, A P Forrest, +5 authors, W D George.
Br J Cancer, 1996 Jul 01; 74(2). PMID: 8688340    Free PMC article.
Changes in serum estrogen levels in women during tamoxifen therapy.
S S Lum, E A Woltering, W S Fletcher, R F Pommier.
Am J Surg, 1997 May 01; 173(5). PMID: 9168075
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG), Monica Castiglione-Gertsch, +7 authors, Richard D Gelber.
J Natl Cancer Inst, 2003 Dec 18; 95(24). PMID: 14679153
Leuprorelin acetate in prostate cancer: a European update.
R Persad.
Int J Clin Pract, 2002 Jul 26; 56(5). PMID: 12137449
Review.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
B Fisher, J Dignam, J Bryant, N Wolmark.
J Natl Cancer Inst, 2001 May 03; 93(9). PMID: 11333290
Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.
Junichi Kurebayashi, Tatsuya Toyama, +2 authors, Tsukasa Fujimoto.
Breast Cancer, 2016 Mar 28; 24(1). PMID: 27017207    Free PMC article.
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.
Guiyun Sohn, Sei Hyun Ahn, +6 authors, Seunghee Baek.
Cancer Res Treat, 2016 Oct 19; 48(4). PMID: 27063654    Free PMC article.
Tamoxifen Pharmacovigilance: Implications for Safe Use in the Future.
Demetra Antimisiaris, Ki-Hwan Gabriel Bae, Laura Morton, Zahara Gully.
Consult Pharm, 2017 Sep 01; 32(9). PMID: 28855012    Free PMC article.
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Yasuo Ohashi, Eiichi Shiba, +5 authors, Tsukasa Fujimoto.
Support Care Cancer, 2017 Oct 25; 26(3). PMID: 29063390    Free PMC article.
Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Yukinori Ozaki, Yuko Tanabe, +6 authors, Toshimi Takano.
Breast Cancer, 2018 Jan 23; 25(3). PMID: 29357022    Free PMC article.
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers.
Michael Ulm, Arvind V Ramesh, +3 authors, Ramesh Narayanan.
Endocr Connect, 2019 Jan 15; 8(2). PMID: 30640710    Free PMC article.
Review.
Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
Georges Tanios, Nicolas Andrews Mungo, Aaysha Kapila, Kailash Bajaj.
BMJ Case Rep, 2017 Jul 16; 2017. PMID: 28710301    Free PMC article.
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Junichi Kurebayashi, Eiichi Shiba, +6 authors, Yasuo Ohashi.
Breast Cancer, 2021 Feb 28; 28(3). PMID: 33638810    Free PMC article.